-- 2025 adjusted diluted EPS of greater than $7.25 --
-- Reaffirms 2024 adjusted diluted EPS guidance of greater than $6.80 --
Chief Executive Officer of Centene, Sarah M. London. "This morning, we are reiterating our 2024 adjusted diluted EPS guidance of greater than $6.80. Additionally, we issued 2025 adjusted diluted EPS guidance of greater than $7.25, representing more than 6% year-over-year growth."
For its 2025 fiscal year, the Company's guidance is as follows:
- Total revenues of $166.5 billion to $169.5 billion.
- Premium and service revenues of $154.0 billion to $156.0 billion.
- GAAP diluted earnings per share (EPS) of greater than $6.19.
- Adjusted diluted EPS of greater than $7.25.
- Health benefits ratio (HBR) of 88.4% to 89.0%.
- Selling, general and administrative (SG&A) expense ratio of 8.1% to 8.7%.
- Adjusted SG&A expense ratio of 8.1% to 8.7%.
- Effective tax rate of 21.5% to 22.5%.
- Adjusted effective tax rate of 22.0% to 23.0%.
- Diluted shares outstanding of 491.0 million to 494.0 million.
The Company reaffirms its 2024 premium and service revenues guidance in the previously announced range of $143.5 billion to $144.5 billion, HBR guidance in the previously announced range of 88.3% to 88.5% and adjusted diluted EPS guidance of greater than $6.80. Full year 2024 earnings will be reported on February 4, 2025, at 6:00 a.m. Eastern Time, with a conference call at 8:30 a.m. Eastern Time.
Investor Meeting
Centene Corporation will host a virtual investor day today starting at 8:30 a.m. Eastern Time. The event can be accessed via a live webcast on the Company's website at www.centene.com, under the Investors section, or directly via the following link at: https://event.webcasts.com/starthere.jsp?ei=1700085&tp_key=eac9720ef1. A webcast replay will be available for on-demand listening shortly following the completion of the call for the next 12 months at the aforementioned URL.
https://www.prnewswire.com/news-releases/centene-corporation-announces-2025-guidance-302329665.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.